Clinical trial
Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients…
NCT00314912 · Bellus Health Inc. - a GSK company, Industry · Unknown status
Key facts
| NCT number | NCT00314912 |
|---|---|
| Title | Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease |
| Official title | An Open-Label Extension of the Phase III Study CL-758007 With Tramiprosate (3APS) in Patients With Alzheimer's Disease |
| Lead sponsor | Bellus Health Inc. - a GSK company, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Tramiprosate (3APS) |
| Enrollment | 650 |
| Start date | May 1, 2006 |
| First posted | Apr 17, 2006 |
| Last update posted | Jul 16, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: